Phytocannabinoids as novel therapeutic agents in CNS disorders

Pharmacology and Therapeutics

Volumn 133, Issue 1, 2012, Pages 79-97

  Hill, Andrew J ^a   Williams, Claire M ^a   Whalley, Benjamin J ^a   Stephens, Gary J ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Cannabinoids; Electrophysiology; Endocannabinoid system; Epilepsy; Feeding

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABIDIOL; CANNABIDIVARIN; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; DELTA 9 TETRAHYDROCANNABIVARIN; DIAZEPAM; DRONABINOL; ETHOSUXIMIDE; NABILONE; NABIXIMOLS; PHENOBARBITAL; PHENYTOIN; RIMONABANT; TRIMETHADIONE; UNCLASSIFIED DRUG;

AFFECTIVE NEUROSIS; ALZHEIMER DISEASE; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DEPRESSION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG TARGETING; EPILEPSY; FEEDING; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SEIZURE;

EID: 83555174546     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.09.002     Document Type: Review

References (319)

1. M.E. Abood, G. Rizvi, N. Sallapudi, and S.D. Mcallister Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity Neurosci Lett 309 2001 197 201
2. V. Agosti, E. Nunes, and F. Levin Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence Am J Drug Alcohol Abuse 28 2002 643 652
3. J. Ahrens, R. Demir, M. Leuwer, J. De La Roche, K. Krampfl, and N. Foadi The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function Pharmacology 83 2009 217 222
4. B.E. Alger, and J. Kim Supply and demand for endocannabinoids Trends Neurosci 34 2011 304 315
5. F.R. Ames, and S. Cridland Anticonvulsant effect of cannabidiol S Afr Med J 69 1986 14
6. A. Arevalo-Martin, D. Garcia-Ovejero, O. Gomez, A. Rubio-Araiz, B. Navarro-Galve, and C. Guaza CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies Br J Pharmacol 153 2008 216 225
7. A. Arevalo-Martin, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J Neurosci 23 2003 2511 2516
8. J.C. Arnold, G.E. Hunt, and I.S. Mcgregor Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats Life Sci 70 2001 97 108
9. C.H. Ashton Pharmacology and effects of cannabis: a brief review Br J Psychiatry 178 2001 101 106
10. H. Ashton, J. Golding, V.R. Marsh, J.E. Millman, and J.W. Thompson The seed and the soil: effect of dosage, personality and starting state on the response to delta 9 tetrahydrocannabinol in man Br J Clin Pharmacol 12 1981 705 720
11. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and J.W. Huffman Cannabinoids control spasticity and tremor in a multiple sclerosis model Nature 404 2000 84 87
12. M.P. Barnes Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain Expert Opin Pharmacother 7 2006 607 615
13. J.E. Beal, R. Olson, L. Laubenstein, J.O. Morales, P. Bellman, and B. Yangco Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS J Pain Symptom Manage 10 1995 89 97
14. M.M. Bergamaschi, R.H. Queiroz, M.H. Chagas, D.C. De Oliveira, B.S. De Martinis, and F. Kapczinski Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients Neuropsychopharmacology 36 2011 1219 1226
15. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, and I. Brandi Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Br J Pharmacol 134 2001 845 852
16. R.M. Bitencourt, F.A. Pamplona, and R.N. Takahashi Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats Eur Neuropsychopharmacol 18 2008 849 859
17. C. Blazquez, A. Chiarlone, O. Sagredo, T. Aguado, M.R. Pazos, and E. Resel Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease Brain 134 2011 119 136
18. W.O. Boggan, R.A. Steele, and D.X. Freedman 9 -Tetrahydrocannabinol effect on audiogenic seizure susceptibility Psychopharmacologia 29 1973 101 106
19. D. Bolognini, B. Costa, S. Maione, F. Comelli, P. Marini, and V. Di Marzo The plant cannabinoid delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice Br J Pharmacol 160 2010 677 687
20. L.M. Bornheim, and M.P. Grillo Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator Chem Res Toxicol 11 1998 1209 1216
21. British Medical Association Therapeutic uses of cannabis 1997 Harwood Academic Australia
22. S.P. Brown, P.K. Safo, and W.G. Regehr Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels J Neurosci 24 2004 5623 5631
23. J.D. Buckner, and N.B. Schmidt Marijuana effect expectancies: relations to social anxiety and marijuana use problems Addict Behav 33 2008 1477 1483
24. G.A. Cabral, and L. Griffin-Thomas Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation Expert Rev Mol Med 11 2009 e3
25. E.A. Carlini, and J.M. Cunha Hypnotic and antiepileptic effects of cannabidiol J Clin Pharmacol 21 1981 417S 427S
26. E.J. Carrier, J.A. Auchampach, and C.J. Hillard Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression Proc Natl Acad Sci U S A 103 2006 7895 7900
27. E.J. Carrier, C.S. Kearn, A.J. Barkmeier, N.M. Breese, W. Yang, and K. Nithipatikom Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism Mol Pharmacol 65 2004 999 1007
28. C.B. Carroll, P.G. Bain, L. Teare, X. Liu, C. Joint, and C. Wroath Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study Neurology 63 2004 1245 1250
29. M.G. Cascio, L.A. Gauson, L.A. Stevenson, R.A. Ross, and R.G. Pertwee Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist Br J Pharmacol 159 2010 129 141
30. L.K. Cat, and R.L. Coleman Treatment for HIV wasting syndrome Ann Pharmacother 28 1994 595 597
31. F. Chaperon, P. Soubrie, A.J. Puech, and M.H. Thiebot Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats Psychopharmacology (Berl) 135 1998 324 332
32. Y. Chen, and J. Buck Cannabinoids protect cells from oxidative cell death: a receptor-independent mechanism J Pharmacol Exp Ther 293 2000 807 812
33. V. Chevaleyre, K.A. Takahashi, and P.E. Castillo Endocannabinoid-mediated synaptic plasticity in the CNS Annu Rev Neurosci 29 2006 37 76
34. R.N. Chopra, and G.S. Chopra The present position of hemp drug addiction in India Ind Med Res Mem 31 1939 1 119
35. P. Chiu, R. Karler, C. Craven, D.M. Olsen, and S.A. Turkanis The influence of delta9-tetrahydrocannabinol, cannabinol and cannabidiol on tissue oxygen consumption Res Commun Chem Pathol Pharmacol 12 1975 267 286
36. P. Chiu, D.M. Olsen, H.K. Borys, R. Karler, and S.A. Turkanis The influence of cannabidiol and delta9-tetrahydrocannabinol on cobalt epilepsy in rats Epilepsia 20 1979 365 375
37. R. Christensen, P.K. Kristensen, E.M. Bartels, H. Bliddal, and A. Astrup Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 2007 1706 1713
38. Clinical Neurology Research Group CUPID 2009 Exeter & Plymotuh CNRG
39. B.K. Colasanti, C. Lindamood III, and C.R. Craig Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats Pharmacol Biochem Behav 16 1982 573 578
40. C. Collin, P. Davies, I.K. Mutiboko, and S. Ratcliffe Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis Eur J Neurol 14 2007 290 296
41. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
42. P. Consroe, M.A. Benedito, J.R. Leite, E.A. Carlini, and R. Mechoulam Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice Eur J Pharmacol 83 1982 293 298
43. P. Consroe, and B.S. Fish Behavioral pharmacology of tetrahydrocannabinol convulsions in rabbits Commun Psychopharmacol 4 1980 287 291
44. P. Consroe, J. Laguna, J. Allender, S. Snider, L. Stern, and R. Sandyk Controlled clinical trial of cannabidiol in Huntington's disease Pharmacol Biochem Behav 40 1991 701 708
45. P. Consroe, A. Martin, and V. Singh Antiepileptic potential of cannabidiol analogs J Clin Pharmacol 21 1981 428S 436S
46. P. Consroe, and R. Mechoulam Anticonvulsant and neurotoxic effects of tetrahydrocannabinol stereoisomers NIDA Res Monogr 79 1987 59 66
47. P. Consroe, R. Sandyk, and S.R. Snider Open label evaluation of cannabidiol in dystonic movement disorders Int J Neurosci 30 1986 277 282
48. P. Consroe, and A. Wolkin Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats J Pharmacol Exp Ther 201 1977 26 32
49. P.F. Consroe, and A.L. Wolkin Anticonvulsant interaction of cannabidiol and ethosuximide in rats J Pharm Pharmacol 29 1977 500 501
50. P.F. Consroe, G.C. Wood, and H. Buchsbaum Anticonvulsant nature of marihuana smoking JAMA 234 1975 306 307
51. V. Corral Differential effects of medical marijuana based on strain and route of administration: a three-year observational study J Cannabis Ther 1 2001 43 59
52. B. Costa, G. Giagnoni, C. Franke, A.E. Trovato, and M. Colleoni Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation Br J Pharmacol 143 2004 247 250
53. D. Cota, G. Marsicano, B. Lutz, V. Vicennati, G.K. Stalla, and R. Pasquali Endogenous cannabinoid system as a modulator of food intake Int J Obes Relat Metab Disord 27 2003 289 301
54. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
55. J.A. Crippa, G.N. Derenusson, T.B. Ferrari, L. Wichert-Ana, F.L. Duran, and R. Martin-Santos Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report J Psychopharmacol 25 2011 121 130
56. J.A. Crippa, A.W. Zuardi, G.E. Garrido, L. Wichert-Ana, R. Guarnieri, and L. Ferrari Effects of cannabidiol (CBD) on regional cerebral blood flow Neuropsychopharmacology 29 2004 417 426
57. J.A. Crippa, A.W. Zuardi, R. Martin-Santos, S. Bhattacharyya, Z. Atakan, and P. Mcguire Cannabis and anxiety: a critical review of the evidence Hum Psychopharmacol 24 2009 515 523
58. L. Cristino, K. Starowicz, L. De Petrocellis, J. Morishita, N. Ueda, and V. Guglielmotti Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain Neuroscience 151 2008 955 968
59. J.L. Croxford, and S.D. Miller Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 J Clin Invest 111 2003 1231 1240
60. A. Curtis, I. Mitchell, S. Patel, N. Ives, and H. Rickards A pilot study using nabilone for symptomatic treatment in Huntington's disease Mov Disord 24 2009 2254 2259
61. J.P. Davis, and H.H. Ramsey Antiepileptic action of marijuana-active substances Fed Proc Baltimore 8 1949 284 285
62. E.P. De Meijer, M. Bagatta, A. Carboni, P. Crucitti, V.M. Moliterni, and P. Ranalli The inheritance of chemical phenotype in Cannabis sativa L Genetics 163 2003 335 346
63. D.G. Demuth, and A. Molleman Cannabinoid signalling Life Sci 78 2006 549 563
64. L. De Petrocellis, A. Ligresti, A.S. Moriello, M. Allara, T. Bisogno, and S. Petrosino Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes Br J Pharmacol 163 2011 1479 1494
65. L. De Petrocellis, V. Vellani, A. Schiano-Moriello, P. Marini, P.C. Magherini, and P. Orlando Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8 J Pharmacol Exp Ther 325 2008 1007 1015
66. I. Dennis, B.J. Whalley, and G.J. Stephens Effects of delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes Br J Pharmacol 154 2008 1349 1358
67. T.F. Denson, and M. Earleywine Decreased depression in marijuana users Addict Behav 31 2006 738 742
68. V. Deroche-Gamonet, M. Le Moal, P.V. Piazza, and P. Soubrie SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats Psychopharmacology (Berl) 157 2001 254 259
69. K.P. Desanty, and M.S. Dar Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice Pharmacol Biochem Behav 69 2001 251 259
70. K.P. Desanty, and M.S. Dar Involvement of the cerebellar adenosine A1 receptor in cannabinoid-induced motor incoordination in the acute and tolerant state in mice Brain Res 905 2001 178 187
71. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
72. R. Deyo, and R. Musty A cannabichromene (CBC) extract alters behavioral despair on the mouse tail suspension test of depression 2003 Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, VT 2003 147
73. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 2008 438 455
74. V. Di Marzo The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation Pharmacol Res 60 2009 77 84
75. V. Di Marzo, L. De Petrocellis, and T. Bisogno The biosynthesis, fate and pharmacological properties of endocannabinoids Handb Exp Pharmacol 2005 147 185
76. V. Di Marzo, and A. Fontana Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone' Prostaglandins Leukot Essent Fatty Acids 53 1995 1 11
77. V. Di Marzo, A. Ligresti, and L. Cristino The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation Int J Obes (Lond) 33 Suppl 2 2009 S18 S24
78. F. Docagne, V. Muneton, D. Clemente, C. Ali, F. Loria, and F. Correa Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation Mol Cell Neurosci 34 2007 551 561
79. G. Dorard, S. Berthoz, O. Phan, M. Corcos, and C. Bungener Affect dysregulation in cannabis abusers: a study in adolescents and young adults Eur Child Adolesc Psychiatry 17 2008 274 282
80. M.J. Dowie, M.L. Howard, L.F. Nicholson, R.L. Faull, A.J. Hannan, and M. Glass Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice Neuroscience 170 2010 324 336
81. M. Dumont, and M.F. Beal Neuroprotective strategies involving ROS in Alzheimer disease Free Radic Biol Med 51 2011 1014 1026
82. J. Echegoyen, C. Armstrong, R.J. Morgan, and I. Soltesz Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model Epilepsy Res 85 2009 123 127
83. J. Ehrhart, D. Obregon, T. Mori, H. Hou, N. Sun, and Y. Bai Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation J Neuroinflammation 2 2005 29
84. A.T. El-Alfy, K. Ivey, K. Robinson, S. Ahmed, M. Radwan, and D. Slade Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Pharmacol Biochem Behav 95 2010 434 442
85. A.B. El-Remessy, I.E. Khalil, S. Matragoon, G. Abou-Mohamed, N.J. Tsai, and P. Roon Neuroprotective effect of (-)delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite Am J Pathol 163 2003 1997 2008
86. J.M. Ellis Cholinesterase inhibitors in the treatment of dementia J Am Osteopath Assoc 105 2005 145 158
87. M.A. Elsohly, and D. Slade Chemical constituents of marijuana: the complex mixture of natural cannabinoids Life Sci 78 2005 539 548
88. G. Esposito, D. De Filippis, M.C. Maiuri, D. De Stefano, R. Carnuccio, and T. Iuvone Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement Neurosci Lett 399 2006 91 95
89. G. Esposito, C. Scuderi, C. Savani, L. Steardo Jr., D. De Filippis, and P. Cottone Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression Br J Pharmacol 151 2007 1272 1279
90. L.M. Eubanks, C.J. Rogers, A.E.T. Beuscher, G.F. Koob, A.J. Olson, and T.J. Dickerson A molecular link between the active component of marijuana and Alzheimer's disease pathology Mol Pharm 3 2006 773 777
91. J.A. Farrimond, A.J. Hill, B.J. Whalley, and C.M. Williams Cannabis constituents modulate delta9-tetrahydrocannabinol-induced hyperphagia in rats Psychopharmacology (Berl) 210 2010 97 106
92. J.A. Farrimond, M.S. Mercier, B.J. Whalley, and C.M. Williams Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation Phytother Res 25 2011 170 188
93. J.A. Farrimond, B.J. Whalley, and C.M. Williams A low- delta9tetrahydrocannabinol cannabis extract induces hyperphagia in rats Behav Pharmacol 21 2010 769 772
94. C.C. Felder, E.M. Briley, J. Axelrod, J.T. Simpson, K. Mackie, and W.A. Devane Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction Proc Natl Acad Sci U S A 90 1993 7656 7660
95. D.M. Fergusson, and L.J. Horwood Early onset cannabis use and psychosocial adjustment in young adults Addiction 92 1997 279 296
96. B.S. Fish, P. Consroe, and R.R. Fox Convulsant-anticonvulsant properties of delta-9-tetrahydrocannabinol in rabbits Behav Genet 13 1983 205 211
97. N. Foadi, M. Leuwer, R. Demir, R. Dengler, V. Buchholz, and J. De La Roche Lack of positive allosteric modulation of mutated alpha1S267I glycine receptors by cannabinoids Naunyn Schmiedebergs Arch Pharmacol 381 2010 477 482
98. R.W. Foltin, J.V. Brady, and M.W. Fischman Behavioral analysis of marijuana effects on food intake in humans Pharmacol Biochem Behav 25 1986 577 582
99. R.W. Foltin, M.W. Fischman, and M.F. Byrne Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory Appetite 11 1988 1 14
100. Food and Drug Administration Guidance for industry: Botanical drug products 2004
101. S.H. Fox, B. Henry, M. Hill, A. Crossman, and J. Brotchie Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Mov Disord 17 2002 1180 1187
102. P. Fusar-Poli, J.A. Crippa, S. Bhattacharyya, S.J. Borgwardt, P. Allen, and R. Martin-Santos Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing Arch Gen Psychiatry 66 2009 95 105
103. J.E. Gallate, and I.S. Mcgregor The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716 Psychopharmacology (Berl) 142 1999 302 308
104. J.E. Gallate, T. Saharov, P.E. Mallet, and I.S. Mcgregor Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist Eur J Pharmacol 370 1999 233 240
105. Y. Gaoni, and R. Mechoulam The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish J Am Chem Soc 93 1971 217 224
106. M. Garcia-Arencibia, L. Ferraro, S. Tanganelli, and J. Fernandez-Ruiz Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats Neurosci Lett 438 2008 10 13
107. M. Garcia-Arencibia, S. Gonzalez, E. De Lago, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties Brain Res 1134 2007 162 170
108. C. Garcia, C. Palomo, M. Garcia-Arencibia, J.A. Ramos, R.G. Pertwee, and J. Fernandez-Ruiz Symptom-relieving and neuroprotective effects of the phytocannabinoid delta9 -THCV in animal models of Parkinson's disease Br J Pharmacol 2011
109. D. Gieringer Medical use of cannabis: experience in California 2001 NY, Haworth Press Binghamton
110. J.M. Gil, and A.C. Rego Mechanisms of neurodegeneration in Huntington's disease Eur J Neurosci 27 2008 2803 2820
111. G.L. Gilbert, H.J. Kim, J.J. Waataja, and S.A. Thayer Delta9-tetrahydrocannabinol protects hippocampal neurons from excitotoxicity Brain Res 1128 2007 61 69
112. S.A. Golech, R.M. Mccarron, Y. Chen, J. Bembry, F. Lenz, and R. Mechoulam Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors Brain Res Mol Brain Res 132 2004 87 92
113. S. Gonzalez, C. Scorticati, M. Garcia-Arencibia, R. De Miguel, J.A. Ramos, and J. Fernandez-Ruiz Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease Brain Res 1073-1074 2006 209 219
114. L. Grinspoon, and J.B. Bakalar Marihuana, the forbidden medicine 1997 CT, Yale University Press New Haven
115. W.R. Gowers A manual of diseases of the nervous system 1888 P. Blakiston Son & Co. Philadelphia, PA
116. 9-THC in primary anorexia nervosa J Clin Psychopharmacol 3 1983 165 171
117. D.W. Gross, J. Hamm, N.L. Ashworth, and D. Quigley Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center Neurology 62 2004 2095 2097
118. F. Grotenhermen, and M. Schnelle Survey on the medical use of cannabis and THC in Germany J Cannabis Ther 3 2003 17 40
119. S. Guggenhuber, K. Monory, B. Lutz, and M. Klugmann AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity PLoS One 5 2010 e15707
120. F.S. Guimaraes, T.M. Chiaretti, F.G. Graeff, and A.W. Zuardi Antianxiety effect of cannabidiol in the elevated plus-maze Psychopharmacology (Berl) 100 1990 558 559
121. GW Pharmaceuticals Investigator Brochure - Cannabis based medicine extract sublingual formulations 2001
122. J.E. Hallak, S.M. Dursun, D.C. Bosi, L.R. De Macedo, J.P. Machado-De-Sousa, and J. Abrao The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects Prog Neuropsychopharmacol Biol Psychiatry 35 2011 198 202
123. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc Natl Acad Sci U S A 95 1998 8268 8273
124. H. Hasseldam, and F.F. Johansen Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis Neuroimmunomodulation 17 2010 252 264
125. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, and B.R. De Costa Cannabinoid receptor localization in brain Proc Natl Acad Sci U S A 87 1990 1932 1936
126. M. Hickson Malnutrition in ageing Postgrad Med J 82 2006 2 8
127. S. Higgs, C.M. Williams, and T.C. Kirkham Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716 Psychopharmacology (Berl) 165 2003 370 377
128. A.J. Hill, S.E. Weston, N.A. Jones, I. Smith, S.A. Bevan, and E.M. Williamson Delta-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats Epilepsia 51 2010 1522 1532
129. A.J. Hill, N.A. Jones, G.J. Stephens, C.M. Williams, and B.J. Whalley Anticonvulsant effects of GWP42006 in vitro and in vivo in rat Physiology 2010 Meeting abstract, University of Manchester, UK 2010
130. J.V. Hindle Ageing, neurodegeneration and Parkinson's disease Age Ageing 39 2010 156 161
131. L.E. Hollister Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine Clin Pharmacol Ther 12 1971 44 49
132. J.G. Horswill, U. Bali, S. Shaaban, J.F. Keily, P. Jeevaratnam, and A.J. Babbs PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats Br J Pharmacol 152 2007 805 814
133. House of Lords Cannabis: the scientific and medical evidence Stationery office: House of Lords Committee on Science and Technology, London 1998
134. A.C. Howlett The cannabinoid receptors Prostaglandins Other Lipid Mediat 68-69 2002 619 631
135. M.J. Hurley, D.C. Mash, and P. Jenner Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain J Neural Transm 110 2003 1279 1288
136. B. Ignatowska-Jankowska, M.M. Jankowski, and A.H. Swiergiel Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors Neurosci Lett 490 2011 82 84
137. M. Innamorati, M. Pompili, V. Ferrari, P. Girardi, R. Tatarelli, and A. Tamburello Cannabis use and the risk behavior syndrome in Italian university students: are they related to suicide risk? Psychol Rep 102 2008 577 594
138. A. Inui Cancer anorexia-cachexia syndrome: current issues in research and management CA Cancer J Clin 52 2002 72 91
139. M. Iskedjian, B. Bereza, A. Gordon, C. Piwko, and T.R. Einarson Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Curr Med Res Opin 23 2007 17 24
140. T. Iuvone, G. Esposito, R. Esposito, R. Santamaria, M. Di Rosa, and A.A. Izzo Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells J Neurochem 89 2004 134 141
141. A.A. Izzo, F. Borrelli, R. Capasso, V. Di Marzo, and R. Mechoulam Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb Trends Pharmacol Sci 30 2009 515 527
142. K. Jarvis, M.P. Delbello, N. Mills, I. Elman, S.M. Strakowski, and C.M. Adler Neuroanatomic comparison of bipolar adolescents with and without cannabis use disorders J Child Adolesc Psychopharmacol 18 2008 557 563
143. N.A. Jones, A.J. Hill, I. Smith, S.A. Bevan, C.M. Williams, and B.J. Whalley Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo J Pharmacol Exp Ther 332 2010 569 577
144. H. Kalant Medicinal use of cannabis: history and current status Pain Res Manag 6 2001 80 91
145. R. Karler, W. Cely, and S.A. Turkanis The anticonvulsant activity of cannabidiol and cannabinol Life Sci 13 1973 1527 1531
146. R. Karler, W. Cely, and S.A. Turkanis Anticonvulsant activity of delta9-tetrahydrocannabilol and its 11-hydroxy and 8alpha, 11-dihydroxy metabolites in the frog Res Commun Chem Pathol Pharmacol 9 1974 441 452
147. R. Karler, W. Cely, and S.A. Turkanis Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids Life Sci 15 1974 931 947
148. R. Karler, and S.A. Turkanis The antiepileptic potential of the cannabinoids 1976 Plenum Medical Book Company New York
149. R. Karler, and S.A. Turkanis Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice Br J Pharmacol 68 1980 479 484
150. R. Karler, and S.A. Turkanis The cannabinoids as potential antiepileptics J Clin Pharmacol 21 1981 437S 448S
151. J.E. Kelsey, O. Harris, and J. Cassin The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease Behav Brain Res 203 2009 304 307
152. T.C. Kirkham Endocannabinoids and the neurochemistry of gluttony J Neuroendocrinol 20 2008 1099 1100
153. J. Kotin, R.M. Post, and F.K. Goodwin 9 -Tetrahydrocannabinol in depressed patients Arch Gen Psychiatry 28 1973 345 348
154. R. Kozan, M. Ayyildiz, and E. Agar The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats Epilepsia 50 2009 1760 1767
155. E. Kozela, M. Pietr, A. Juknat, N. Rimmerman, R. Levy, and Z. Vogel Cannabinoids delta9-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells J Biol Chem 285 2010 1616 1626
156. F.R. Kreitzer, and N. Stella The therapeutic potential of novel cannabinoid receptors Pharmacol Ther 122 2009 83 96
157. S. Krishnan, R. Cairns, and R. Howard Cannabinoids for the treatment of dementia Cochrane Database Syst Rev CD007204 2009
158. P. Kumar, H. Kalonia, and A. Kumar Huntington's disease: pathogenesis to animal models Pharmacol Rep 62 2010 1 14
159. S.E. Lakhan, and M. Rowland Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review BMC Neurol 9 2009 59
160. I. Lastres-Becker, N. Bizat, F. Boyer, P. Hantraye, J. Fernandez-Ruiz, and E. Brouillet Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo Neuroreport 15 2004 2375 2379
161. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiol Dis 19 2005 96 107
162. C.J. Ledgerwood, S.M. Greenwood, R.R. Brett, J.A. Pratt, and T.J. Bushell Cannabidiol inhibits synaptic transmission in rat hippocampal cultures and slices via multiple receptor pathways Br J Pharmacol 162 2011 286 294
163. H.K. Lee, E.B. Choi, and C.S. Pak The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents Curr Top Med Chem 9 2009 482 503
164. Y.J. Lee, S.B. Han, S.Y. Nam, K.W. Oh, and J.T. Hong Inflammation and Alzheimer's disease Arch Pharm Res 33 2010 1539 1556
165. I.E. Leppik, and A.K. Birnbaum Epilepsy in the elderly Ann N Y Acad Sci 1184 2010 208 224
166. M. Lerner Marihuana: Tetrahydrocannabinol and Related Compounds Science 140 1963 175 176
167. H.L. Li, and H. Lin An archaeological and historical account of cannabis in China Econ Bot 28 4 1974 437 447
168. G.I. Liou, J.A. Auchampach, C.J. Hillard, G. Zhu, B. Yousufzai, and S. Mian Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor Invest Ophthalmol Vis Sci 49 2008 5526 5531
169. R. Lorenz On the application of cannabis in paediatrics and epileptology Neuro Endocrinol Lett 25 2004 40 44
170. W. Loscher Animal models of intractable epilepsy Prog Neurobiol 53 1997 239 258
171. I. Lozano The therapeutic use of Cannabis sativa L. in Arabic medicine J Cannabis Ther 1 2001 63 70
172. M.E. Lull, and M.L. Block Microglial activation and chronic neurodegeneration Neurotherapeutics 7 2010 354 365
173. B. Lutz On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures Biochem Pharmacol 68 2004 1691 1698
174. W.D. Lyman, J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis J Neuroimmunol 23 1989 73 81
175. Y.L. Ma, S.E. Weston, B.J. Whalley, and G.J. Stephens The phytocannabinoid delta9-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum Br J Pharmacol 154 2008 204 215
176. I. Magen, Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam, and E.M. Berry Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation J Hepatol 51 2009 528 534
177. I. Magen, Y. Avraham, Z. Ackerman, L. Vorobiev, R. Mechoulam, and E.M. Berry Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation Br J Pharmacol 159 2010 950 957
178. D.T. Malone, D. Jongejan, and D.A. Taylor Cannabidiol reverses the reduction in social interaction produced by low dose delta9-tetrahydrocannabinol in rats Pharmacol Biochem Behav 93 2009 91 96
179. K. Maresz, G. Pryce, E.D. Ponomarev, G. Marsicano, J.L. Croxford, and L.P. Shriver Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat Med 13 2007 492 497
180. A.M. Martin-Moreno, D. Reigada, B.G. Ramirez, R. Mechoulam, N. Innamorato, and A. Cuadrado Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers' disease Mol Pharmacol 79 2011 964 973
181. A.R. Martin, P. Consroe, V.V. Kane, V. Shah, V. Singh, and N. Lander Structure-anticonvulsant activity relationships of cannabidiol analogs NIDA Res Monogr 79 1987 48 58
182. P. Martin, and P. Consroe Tolerance to delta9-tetrahydrocannabinol in adapted and nonadapted rabbits Pharmacol Biochem Behav 9 1978 753 758
183. C.N. Martyn, L.S. Illis, and J. Thom Nabilone in the treatment of multiple sclerosis Lancet 345 1995 579
184. R. Mason, and J.F. Cheer Cannabinoid receptor activation reverses kainate-induced synchronized population burst firing in rat hippocampus Front Integr Neurosci 3 2009 13
185. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
186. P. Mcgrath Reflections on nutritional issues associated with cancer therapy Cancer Pract 10 2002 94 101
187. R.R. McMeens Cannabis indica in convulsions West Lancet 1856 327 331
188. R.R. McMeens Report of the Ohio State Medical Committee on Cannabis indica 1860 White Sulphur Springs OH, Ohio State Medical Society
189. R. Mechoulam The pharmacohistory of Cannabis sativa 1986 FL, CRC Press Boca Raton
190. R. Mechoulam Plant cannabinoids: a neglected pharmacological treasure trove Br J Pharmacol 146 2005 913 915
191. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, and A.R. Schatz Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem Pharmacol 50 1995 83 90
192. R. Mechoulam, A. Shani, H. Edery, and Y. Grunfeld Chemical basis of hashish activity Science 169 1970 611 612
193. Z. Mehmedic, S. Chandra, D. Slade, H. Denham, S. Foster, and A.S. Patel Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008 J Forensic Sci 55 2010 1209 1217
194. J.P. Meschler, A.C. Howlett, and B.K. Madras Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5, 6-tetrahydropyridine (MPTP)-treated non-human primates Psychopharmacology (Berl) 156 2001 79 85
195. A.C. Moffat The legalization of Cannabis for medical use Sci Justice 42 2002 55 57
196. K. Monory, F. Massa, M. Egertova, M. Eder, H. Blaudzun, and R. Westenbroek The endocannabinoid system controls key epileptogenic circuits in the hippocampus Neuron 51 2006 455 466
197. F.A. Moreira, D.C. Aguiar, and F.S. Guimaraes Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test Prog Neuropsychopharmacol Biol Psychiatry 30 2006 1466 1471
198. J. Morris, and L. Volicer Nutritional management of individuals with Alzheimer's disease and other progressive dementias Nutr Clin Care 4 2001 148 155
199. K. Mortati, B. Dworetzky, and O. Devinsky Marijuana: an effective antiepileptic treatment in partial epilepsy? A case report and review of the literature Rev Neurol Dis 4 2007 103 106
200. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
201. R. Musty, and R. Deyo A cannabigerol (CBC) extract alters behavioral dispair in an animal model of depression 16th Annual Symposium on the Cannabinoids, International Cannabinoid Research Society, Burlington, VT 2006 32
202. T. Nevalainen, and A.J. Irving GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem 10 2010 799 813
203. S.K. Ng, J.C. Brust, W.A. Hauser, and M. Susser Illicit drug use and the risk of new-onset seizures Am J Epidemiol 132 1990 47 57
204. W. Notcutt, M. Price, and G. Chapman Clinical experience with nabilone for chronic pain Pharm Sci 3 1997 551 555
205. A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, and O. Zapletalova A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis Eur J Neurol 2011
206. E. Nunez, C. Benito, M.R. Pazos, A. Barbachano, O. Fajardo, and S. Gonzalez Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study Synapse 53 2004 208 213
207. W.B. O'Shaughnessy On the preparations of the Indian hemp, or gunjah (Cannabis indica) Trans Med Phys Soc Bengal 1840 71 102
208. E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, A. Perchuk, and P.A. Meozzi Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain Ann N Y Acad Sci 1074 2006 514 536
209. M. Oz Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids Pharmacol Ther 111 2006 114 144
210. U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali The emerging role of the endocannabinoid system in endocrine regulation and energy balance Endocr Rev 27 2006 73 100
211. D. Parolaro, N. Realini, D. Vigano, C. Guidali, and T. Rubino The endocannabinoid system and psychiatric disorders Exp Neurol 224 2010 3 14
212. S. Patel, and C.J. Hillard Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice J Pharmacol Exp Ther 297 2001 629 637
213. M.P. Patricelli, and B.F. Cravatt Characterization and manipulation of the acyl chain selectivity of fatty acid amide hydrolase Biochemistry 40 2001 6107 6115
214. H.L. Paulson The spinocerebellar ataxias J Neuroophthalmol 29 2009 227 237
215. D.P. Perl Neuropathology of Alzheimer's disease Mt Sinai J Med 77 2010 32 42
216. C. Perras Sativex for the management of multiple sclerosis symptoms Issues Emerg Health Technol 2005 1 4
217. R.G. Pertwee GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152 2007 984 986
218. R.G. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin Br J Pharmacol 153 2008 199 215
219. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, and M.R. Elphick International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev 62 2010 588 631
220. R.G. Pertwee, R.A. Ross, S.J. Craib, and A. Thomas (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens Eur J Pharmacol 456 2002 99 106
221. D.J. Petro Seizure Disorders 1997 McFarland and Co Jefferson, NC
222. J. Pistovcakova, A. Sulcova, and B. Leonard Comparison of the effects of cannabidiol in two mouse models of depression Collegium Internationale Neuro -Psychopharmacologicum - Book of Abstracts. Tallinn, Estonia: CINP 2006 56
223. F.T. Pijlman, S.M. Rigter, J. Hoek, H.M. Goldschmidt, and R.J. Niesink Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops Addict Biol 10 2005 171 180
224. T.F. Plasse, R.W. Gorter, S.H. Krasnow, M. Lane, K.V. Shepard, and R.G. Wadleigh Recent clinical experience with dronabinol Pharmacol Biochem Behav 40 1991 695 700
225. M.R. Price, G.L. Baillie, A. Thomas, L.A. Stevenson, M. Easson, and R. Goodwin Allosteric modulation of the cannabinoid CB1 receptor Mol Pharmacol 68 2005 1484 1495
226. L. Qian, P.M. Flood, and J.S. Hong Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy J Neural Transm 117 2010 971 979
227. N. Qin, M.P. Neeper, Y. Liu, T.L. Hutchinson, M.L. Lubin, and C.M. Flores TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons J Neurosci 28 2008 6231 6238
228. F. Rakhshan, T.A. Day, R.D. Blakely, and E.L. Barker Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells J Pharmacol Exp Ther 292 2000 960 967
229. B.G. Ramirez, C. Blazquez, T. Gomez Del Pulgar, M. Guzman, and M.L. De Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J Neurosci 25 2005 1904 1913
230. 9-THC as an effective antidepressant and appetite stimulating agent in advanced cancer patients M.C. Braude, S. Szara, The Pharmacology of Marihuana 1976 Raven Press New York, NY 763 776
231. D. Reilly, P. Didcott, W. Swift, and W. Hall Long-term cannabis use: characteristics of users in an Australian rural area Addiction 93 1998 837 846
232. L.B. Resstel, S.R. Joca, F.A. Moreira, F.M. Correa, and F.S. Guimaraes Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats Behav Brain Res 172 2006 294 298
233. L.B. Resstel, R.F. Tavares, S.F. Lisboa, S.R. Joca, F.M. Correa, and F.S. Guimaraes 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Br J Pharmacol 156 2009 181 188
234. J.R. Reynolds Therapeutical uses and toxic effects of Cannabis indica Lancet 1 1868 637 638
235. G. Riedel, P. Fadda, S. Mckillop-Smith, R.G. Pertwee, B. Platt, and L. Robinson Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice Br J Pharmacol 156 2009 1154 1166
236. J.R. Rivers, and J.C. Ashton The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies Cent Nerv Syst Agents Med Chem 10 2010 47 64
237. P. Robson Therapeutic aspects of cannabis and cannabinoids Br J Psychiatry 178 2001 107 115
238. D.J. Rog Cannabis-based medicines in multiple sclerosis-a review of clinical studies Immunobiology 215 2010 658 672
239. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 2005 812 819
240. D.J. Rog, T.J. Nurmikko, and C.A. Young Oromucosal delta9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clin Ther 29 2007 2068 2079
241. H.R. Ross, I. Napier, and M. Connor Inhibition of recombinant human T-type calcium channels by delta9-tetrahydrocannabinol and cannabidiol J Biol Chem 283 2008 16124 16134
242. R.A. Ross The enigmatic pharmacology of GPR55 Trends Pharmacol Sci 30 2009 156 163
243. L. Ruiz-Valdepenas, J.A. Martinez-Orgado, C. Benito, A. Millan, R.M. Tolon, and J. Romero Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study J Neuroinflammation 8 2011 5
244. E.B. Russo Cannabis in India: Ancient lore and modern medicine R. Mechoulam, Cannabinoids as therapeutics 2005 Birkhäuser Verlag Basel, Switzerland 1 22
245. E. Russo, and G.W. Guy A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med Hypotheses 66 2006 234 246
246. E.B. Russo History of cannabis and its preparations in saga, science, and sobriquet Chem Biodivers 4 2007 1614 1648
247. E.B. Russo Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Br J Pharmacol 163 2011 1344 1364
248. E.B. Russo, A. Burnett, B. Hall, and K.K. Parker Agonistic properties of cannabidiol at 5-HT1a receptors Neurochem Res 30 2005 1037 1043
249. 2+ levels J Neurosci 29 2009 2053 2063
250. A. Saban, A.J. Flisher, and G. Distiller Association between psychopathology and substance use among school-going adolescents in Cape Town, South Africa J Psychoactive Drugs 42 2010 467 476
251. N. Sacks, J.R. Hutcheson Jr., J.M. Watts, and R.E. Webb Case report: the effect of tetrahydrocannabinol on food intake during chemotherapy J Am Coll Nutr 9 1990 630 632
252. O. Sagredo, J.A. Ramos, A. Decio, R. Mechoulam, and J. Fernandez-Ruiz Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors Eur J Neurosci 26 2007 843 851
253. R. Sandyk, S.R. Snider, P. Consroe, and S.M. Elias Cannabidiol in dystonic movement disorders Psychiatry Res 18 1986 291
254. K.A. Schoedel, N. Chen, A. Hilliard, L. White, C. Stott, and E. Russo A randomized, double-blind, placebo-controlled, crossover study to evaluate the abuse potential of nabiximols oromucosal spray in subjects with a history of recreational cannabis use Hum Psychopharmacol 2011 Jun 13 [Epub ahead of print]
255. A.A. Scopinho, F.S. Guimaraes, F.M. Correa, and L.B. Resstel Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists Pharmacol Biochem Behav 98 2011 268 272
256. H. Sharir, and M.E. Abood Pharmacological characterization of GPR55, a putative cannabinoid receptor Pharmacol Ther 126 2010 301 313
257. M. Shen, and S.A. Thayer Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture Mol Pharmacol 55 1999 8 13
258. Y. Shou-Zhong The divine farmer as materia medica: A translation of the Shen Nong Ben Cao Jing 1997 Blue Poppy Press Boulder, CO 198
259. K.A. Sieradzan, S.H. Fox, M. Hill, J.P. Dick, A.R. Crossman, and J.M. Brotchie Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study Neurology 57 2001 2108 2111
260. M.A. Silverdale, S. Mcguire, A. Mcinnes, A.R. Crossman, and J.M. Brotchie Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease Exp Neurol 169 2001 400 406
261. P. Skolnick, B. Legutko, X. Li, and F.P. Bymaster Current perspectives on the development of non-biogenic amine-based antidepressants Pharmacol Res 43 2001 411 423
262. K.A. Smiley, R. Karler, and S.A. Turkanis Effects of cannabinoids on the perfused rat heart Res Commun Chem Pathol Pharmacol 14 1976 659 675
263. R.D. Sofia, and L.C. Knobloch Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats Pharmacol Biochem Behav 4 1976 591 599
264. C. Stadelmann, C. Wegner, and W. Bruck Inflammation, demyelination, and degeneration - recent insights from MS pathology Biochim Biophys Acta 1812 2011 275 282
265. N. Stella Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas Glia 58 2010 1017 1030
266. F. Strasser, D. Luftner, K. Possinger, G. Ernst, T. Ruhstaller, and W. Meissner Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group J Clin Oncol 24 2006 3394 3400
267. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, and K. Itoh 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem Biophys Res Commun 215 1995 89 97
268. K.B. Svendsen, T.S. Jensen, and F.W. Bach Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial BMJ 329 2004 253
269. A. Thomas, G.L. Baillie, A.M. Phillips, R.K. Razdan, R.A. Ross, and R.G. Pertwee Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro Br J Pharmacol 150 2007 613 623
270. A. Thomas, L.A. Stevenson, K.N. Wease, M.R. Price, G. Baillie, and R.A. Ross Evidence that the plant cannabinoid delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist Br J Pharmacol 2005
271. T.D. Thomson, and S.A. Turkanis Barbiturate-induced transmitter release at a frog neuromuscular junction Br J Pharmacol 48 1973 48 58
272. C. Tourino, A. Zimmer, and O. Valverde THC Prevents MDMA Neurotoxicity in Mice PLoS One 5 2010 e9143
273. M. Touw The religious and medicinal uses of Cannabis in China, India and Tibet J Psychoactive Drugs 13 1981 23 34
274. B. Trembly, and M. Sherman Double-blind clinical study of cannabidiol as a secondary anticonvulsant Marijuana '90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete, July 8-11 1990
275. K. Tsou, S. Brown, M.C. Sanudo-Pena, K. Mackie, and J.M. Walker Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system Neuroscience 83 1998 393 411
276. S.A. Turkanis, W. Cely, D.M. Olsen, and R. Karler Anticonvulsant properties of cannabidiol Res Commun Chem Pathol Pharmacol 8 1974 231 246
277. S.A. Turkanis, P. Chiu, H.K. Borys, and R. Karler Influence of delta9-tetrahydrocannabinol and cannabidiol on photically evoked after-discharge potentials Psychopharmacology (Berl) 52 1977 207 212
278. S.A. Turkanis, and R. Karler Influence of anticonvulsant cannabinoids on posttetanic potentiation at isolated bullfrog ganglia Life Sci 17 1975 569 578
279. S.A. Turkanis, and R. Karler Electrophysiologic properties of the cannabinoids J Clin Pharmacol 21 1981 449S 463S
280. S.A. Turkanis, and R. Karler Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat Psychopharmacology (Berl) 75 1981 294 298
281. S.A. Turkanis, and R. Karler Central excitatory properties of delta9-tetrahydrocannabinol and its metabolites in iron-induced epileptic rats Neuropharmacology 21 1982 7 13
282. S.A. Turkanis, and R. Karler Different cannabinoids exhibit different electrophysiological properties NIDA Res Monogr 79 1987 67 81
283. S.A. Turkanis, R. Karler, and L.M. Partlow Differential effects of delta-9-tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells Brain Res 560 1991 245 250
284. S.A. Turkanis, K.A. Smiley, H.K. Borys, D.M. Olsen, and R. Karler An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats Epilepsia 20 1979 351 363
285. M. Van Der Stelt, W.B. Veldhuis, P.R. Bar, G.A. Veldink, J.F. Vliegenthart, and K. Nicolay Neuroprotection by delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity J Neurosci 21 2001 6475 6479
286. I. van Rossum, M. Boomsma, D. Tenback, C. Reed, and J. Van Os Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis J Nerv Ment Dis 197 2009 35 40
287. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, and K. Mackie Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 2005 329 332
288. S.A. van Vliet, R.A. Vanwersch, M.J. Jongsma, B. Olivier, and I.H. Philippens Therapeutic effects of delta9-THC and modafinil in a marmoset Parkinson model Eur Neuropsychopharmacol 18 2008 383 389
289. C. Vaney, M. Heinzel-Gutenbrunner, P. Jobin, F. Tschopp, B. Gattlen, and U. Hagen Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study Mult Scler 10 2004 417 424
290. R.E. Vann, T.F. Gamage, J.A. Warner, E.M. Marshall, N.L. Taylor, and B.R. Martin Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of delta9-tetrahydrocannabinol Drug Alcohol Depend 94 2008 191 198
291. K. Venderová, E. Růzicka, V. Vorísek, and P. Visnovský Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms Mov Disord 19 2004 1102 1106
292. L. Volicer Dronabinol may help behaviour problems in Alzheimers disease Am Fam Physician 55 1997 1338
293. D.T. Wade, P. Makela, P. Robson, H. House, and C. Bateman Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult Scler 10 2004 434 441
294. D.T. Wade, P.M. Makela, H. House, C. Bateman, and P. Robson Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis Mult Scler 12 2006 639 645
295. D.T. Wade, P. Robson, H. House, P. Makela, and J. Aram A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clin Rehabil 17 2003 21 29
296. M.J. Wallace, J.L. Wiley, B.R. Martin, and R.J. Delorenzo Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects Eur J Pharmacol 428 2001 51 57
297. S. Walsh, K. Mnich, K. Mackie, A.M. Gorman, D.P. Finn, and E. Dowd Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat Brain Res Bull 81 2010 543 548
298. S. Walther, R. Mahlberg, U. Eichmann, and D. Kunz Delta-9- tetrahydrocannabinol for nighttime agitation in severe dementia Psychopharmacology (Berl) 185 2006 524 528
299. X. Wang, J.G. Horswill, B.J. Whalley, and G.J. Stephens Effects of the allosteric antagonist 1-(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl) phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum Mol Pharmacol 79 2011 758 767
300. K. Watanabe, Y. Kayano, T. Matsunaga, I. Yamamoto, and H. Yoshimura Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids Biol Pharm Bull 19 1996 1109 1111
301. B.J. Whalley, J.D. Wilkinson, E.M. Williamson, and A. Constanti A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro Neurosci Lett 365 2004 58 63
302. P.S. Whitton Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease Curr Opin Investig Drugs 11 2010 788 794
303. J.L. Wiley, J.J. Burston, D.C. Leggett, O.O. Alekseeva, R.K. Razdan, and A. Mahadevan CB1 cannabinoid receptor-mediated modulation of food intake in mice Br J Pharmacol 145 2005 293 300
304. J.D. Wilkinson, B.J. Whalley, D. Baker, G. Pryce, A. Constanti, and S. Gibbons Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol 55 2003 1687 1694
305. C.M. Williams, and T.C. Kirkham Observational analysis of feeding induced by delta9-THC and anandamide Physiol Behav 76 2002 241 250
306. C.M. Williams, and T.C. Kirkham Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine Pharmacol Biochem Behav 71 2002 333 340
307. C.M. Williams, P.J. Rogers, and T.C. Kirkham Hyperphagia in pre-fed rats following oral delta9-THC Physiol Behav 65 1998 343 346
308. M.M. Wilson, C. Philpot, and J.E. Morley Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?-a pilot study J Nutr Health Aging 11 2007 195 198
309. K.H. Yang, S. Galadari, D. Isaev, G. Petroianu, T.S. Shippenberg, and M. Oz The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine 3A receptor-mediated currents in Xenopus laevis oocytes J Pharmacol Exp Ther 333 2010 547 554
310. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Lancet 362 2003 1517 1526
311. J.P. Zajicek, H.P. Sanders, D.E. Wright, P.J. Vickery, W.M. Ingram, and S.M. Reilly Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up J Neurol Neurosurg Psychiatry 76 2005 1664 1669
312. T.V. Zanelati, C. Biojone, F.A. Moreira, F.S. Guimaraes, and S.R. Joca Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors Br J Pharmacol 159 2010 122 128
313. A. Zani, D. Braida, V. Capurro, and M. Sala Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors Br J Pharmacol 152 2007 1301 1311
314. A. Zuardi, J. Crippa, S. Dursun, S. Morais, J. Vilela, and R. Sanches Cannabidiol was ineffective for manic episode of bipolar affective disorder J Psychopharmacol 24 2010 135 137
315. A.W. Zuardi, J.A. Crippa, J.E. Hallak, F.A. Moreira, and F.S. Guimaraes Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Braz J Med Biol Res 39 2006 421 429
316. A.W. Zuardi, J.A. Crippa, J.E. Hallak, J.P. Pinto, M.H. Chagas, and G.G. Rodrigues Cannabidiol for the treatment of psychosis in Parkinson's disease J Psychopharmacol 23 2009 979 983
317. A.W. Zuardi, F.S. Guimaraes, and A.C. Moreira Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers Braz J Med Biol Res 26 1993 213 217
318. A.W. Zuardi, and I.G. Karniol Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination Braz J Med Biol Res 16 1983 141 146
319. A.W. Zuardi, I. Shirakawa, E. Finkelfarb, and I.G. Karniol Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects Psychopharmacology (Berl) 76 1982 245 250